Viewing nowSarban Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Daewoo Pharmaceutical Co., Ltd.

MFDS item code 200808653 · Notified 2008.08.12 · Insurance code 649602940
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to control blood pressure in patients with essential hypertension. It is also helpful for heart failure patients who are intolerant to ACE inhibitors, especially those classified as NYHA class II to IV. It is effective in reducing the risk of mortality in clinically stable patients with left ventricular dysfunction or impairment of left ventricular contractility after myocardial infarction. Thus, it is beneficial for the management of hypertension, heart failure, and post-myocardial infarction.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When coadministering a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or greater. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefit of treatment outweighs the risk when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension 6) Children: The safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: The safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus, especially during the second and third trimesters, if taken during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be taken by individuals with allergies to this drug or its components, pregnant patients, patients with severe liver disease, or those with significantly impaired kidney function, or those with a history of specific angioedema. Elderly patients, patients with high potassium levels, patients with reduced liver function, or patients with heart valve disease or cardiovascular disease should take this medication with caution and should be closely monitored during treatment. Blood pressure may drop sharply at the beginning of treatment, causing dizziness or fainting; therefore, patients undergoing dialysis or taking diuretics, or those with restricted salt intake should start with a low dose and gradually increase it. This medication may increase potassium levels in the blood; therefore, caution is needed when taken with potassium-sparing diuretics or potassium supplements. Additionally, when used with other antihypertensive drugs or specific anti-inflammatory pain relievers, the blood pressure control effect may be reduced or kidney function may be affected, so it should be taken under the guidance of a physician. During treatment, symptoms such as headaches, dizziness, fatigue, cough, and dyspepsia may occur, and, rarely, severe allergic reactions, kidney function decline, or blood abnormalities may occur, so any unusual symptoms should be reported to healthcare professionals immediately. It is preferable not to take this medication during pregnancy or breastfeeding; if breastfeeding, it is advisable to discontinue nursing while taking this medication. Safety and efficacy in children and adolescents under 18 years of age have not been established, and therefore it is not recommended for use. In case of overdose, severe hypotension or altered consciousness may occur, and immediate medical attention should be sought for proper treatment. This medication should be kept out of reach of children and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is also important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Pale red round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Daewoo Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.